Diabetes drugs reduce severe heart failure events

The diabetes drug Jardiance, or empagliflozin, dramatically cut the risk of cardiovascular events in patients with heart failure and reduced ejection, a new study in NEJM shows. The drug, which is from Boehringer Ingelheim and Eli Lilly, seemed to work in patients with and without diabetes. 

The data were presented during a virtual meeting of the European Society of Cardiology Congress. This is the second clinical trial to show that next-gen diabetes drugs have important cardiovascular benefits for patients with heart failure: Last year, AstraZeneca’s glucose-reducing drug Farxiga also was shown to help reduce cardiovascular events in heart failure patients.